At a glance
ClinicalIndex Comparison RecordPhase 3Completed
Drug / intervention
Oxymorphone Extended Releasedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Titration Followed by a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Oxymorphone Extended Release Tablets in Opioid-Experienced Patients With Chronic Low Back Pain
In Brief
A Phase 3 clinical trial evaluating Oxymorphone Extended Release for Chronic Pain. Completed, across 31 sites.
Detailed Summary
The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in opioid-experienced patients with chronic low back pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pain
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2004
Study CompletionAug 2005
First PostedSep 2005
TodayJul 2026
First PostedSep 27, 2005
Enrollment StartOct 1, 2004
Study CompletionAug 1, 2005
TodayJul 2, 2026
Posted 20.8 years ago
Interventions
Oxymorphone Extended Releasedrug